Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 18, 2008 Brian Orelli	St. Jude Is a Fighter The medical device maker continues to kick the competition while it's down.
The Motley Fool April 20, 2005 Stephen D. Simpson	St. Jude's Healthy Heartbeat Medical device maker St. Jude continues to be boosted by ICD market share gains, and new businesses are coming on line, as well.
The Motley Fool July 20, 2005 Stephen D. Simpson	Hey, Jude! Party Hearty St. Jude's ICD (implantable cardioverter defibrillator) business is on fire and fueling strong profit growth for this medical device maker. Whether your cut-off makes St. Jude a mid-cap or a large-cap, this company is certainly growing -- and the stock's valuation reflects that.
The Motley Fool October 19, 2007 Billy Fisher	Keeping Pace at St. Jude Medical device maker St. Jude Medical has a strong quarter, but investors weren't impressed.
The Motley Fool January 26, 2005 Stephen D. Simpson	St. Jude Is No Lost Cause The No. 3 cardiology company posts solid growth because of continuing implantable cardioverter defibrillator (ICD) market share gains.
The Motley Fool January 25, 2006 Stephen D. Simpson	Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note.
The Motley Fool July 25, 2011 Jason Moser	Rising Star Buy: St. Jude Medical It's a good time to jump in on this medical-device maker.
The Motley Fool July 19, 2006 Stephen D. Simpson	Taking St. Jude's Pulse The ICD market is a long-term opportunity, but not a panacea. St. Jude investors should remember that this is a rough neighborhood -- product liability, FDA bureaucracy, and huge, tough competitors live here, too.
The Motley Fool April 19, 2007 Billy Fisher	A Saintly Quarter Shares of St. Jude Medical rise after the company announces a big quarter.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Busy Day for St. Jude In addition to announcing a major acquisition, St. Jude also reported very solid financial results for the third quarter. Analysts keep raising the bar, and the medical equipment company continues to surpass it.
The Motley Fool January 9, 2007 Billy Fisher	St. Jude's Juiced-Up Q4 The medical-device maker shows stronger vital signs. Investors, take note.
The Motley Fool April 11, 2008 Brian Orelli	St. Jude's Heartfelt Acquisition Medical-device maker St. Jude purchases tiny EP MedSystems.
The Motley Fool January 18, 2012 Dan Caplinger	Has St. Jude Medical Become the Perfect Stock? St. Jude took a big step toward perfection when it initiated a big dividend in early 2011.
The Motley Fool July 25, 2011 Jordan DiPietro	Should You Retire With St. Jude? I can't decide for you whether or not this is the best stock for retirement, but it has passed all four tests, which is pretty impressive.
The Motley Fool April 19, 2006 Stephen D. Simpson	St. Jude Lives and Learns Though dynamics in the ICD market caught it by surprise, this is still a quality med-tech company. Investors, take note.
The Motley Fool February 8, 2006 Tim Beyers	Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's buying now? Dominion Resources... Goodrich Petroleum... iPass... ITT Educational Services... St. Jude Medical...
The Motley Fool October 12, 2004 Jeff Hwang	The Phantom Stock Split "Boost" If St. Jude Medical's stock went up, it's not because it's worth any more.
The Motley Fool April 25, 2011 Arundhati Parmar	St. Jude: New Aortic Replacement Valve Approved St. Jude gets good news.
The Motley Fool June 7, 2011 Arundhati Parmar	St. Jude Medical Introduces Two Cardiac Devices in India St. Jude heads to the Subcontinent.
BusinessWeek June 7, 2004 Gene G. Marcial	St. Jude's Bruise Should Clear Up Fast St. Jude Medical (STJ ) tumbled 2%, to $73, after it revealed that the FDA had delayed for a month the approval of its new Epic CRT-defibrillator.
The Motley Fool April 23, 2011	St. Jude, Medtronic Execs Offer Different Views on JAMA Article's Impact An article and government investigation into implant devices may or may not have played a role in each company's performance, depending on whom you ask.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Stimulating Merger St. Jude will be paying $61.25 a share in cash for Advanced Neuromodulation Systems, a robust 30% premium to Friday's closing price. This deal demonstrates that large med-tech players may still be on the prowl for avenues into fast-growing new markets.
The Motley Fool July 21, 2011 Arundhati Parmar	New Hypertension Treatment from St. Jude Medical? St. Jude management is keeping mum on renal denervation.
BusinessWeek May 29, 2006 Gene G. Marcial	Will Medtronic's Pulse Quicken? Some investors say Medtronic may beat analysts' consensus forecast.
The Motley Fool June 24, 2011 Arundhati Parmar	Data on St. Jude Migraine Treatment "Impressive" An effective migraine treatment would be very valuable for St. Jude.
The Motley Fool June 24, 2009 Brian Orelli	Boston Scientific Helps Itself ... and Its Rivals Boston Scientific released positive results from a clinical trial testing its heart devices, but unfortunately the data is likely to help its competitors as well.
The Motley Fool April 5, 2006 Stephen D. Simpson	St. Jude's Racing Heartbeat Slows Even though the stock got far too expensive, this is still a good company and could still be a viable target for certain large health-care companies that may be in an acquisition frame of mind.
The Motley Fool June 27, 2011 Arundhati Parmar	St. Jude Medical's Migraine Treatment: Good for Europe, but Not the U.S.? St. Jude won't comment on whether the company plans to do a second clinical trial or whether it is confident it will win approval from the FDA without it.
The Motley Fool November 18, 2004 W.D. Crotty	Medtronic Down, Not Out Internal defibrillator maker's earnings growth rate is slowing down, but its future looks healthy.
BusinessWeek April 12, 2004 Gene G. Marcial	Taking Heart At ATS Medical New management at ATS Medical, a maker of mechanical heart valves, is giving shareholders fresh hope.
The Motley Fool July 12, 2011 Arundhati Parmar	FDA Allows Expansion of St. Jude Study to Treat Severe Depression St. Jude moves forward with treatment for depression.
The Motley Fool May 26, 2005 Stephen D. Simpson	A Second Opinion on Medtronic Medtronic is a growth stalwart, but does valuation properly account for the challenges?
The Motley Fool August 4, 2006 Stephen D. Simpson	Medtronic's Shock to the System Its guidance cuts rattled the med-tech industry, but long-term trends remain positive. While the going may be tougher now in the ICD space, it's still an attractive long-term opportunity, and investors may want to start looking around for bargains.
The Motley Fool January 6, 2005 Stephen D. Simpson	Can Medtronic Still Quicken the Pulse? While increased competition looms for the medical device maker, a shareholder update looks to the past.
The Motley Fool April 20, 2007	St. Jude Makes It Better: Fool by Numbers The medical device maker released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool October 4, 2004 Selena Maranjian	When Medicare Boosts Stocks More defibrillators in use means higher earnings for some investors.
The Motley Fool November 21, 2006 Ryan Fuhrmann	Shocking Results at Medtronic Favorable earnings boost shares of this medical equipment maker -- but are they too high already?
The Motley Fool December 17, 2011 Stephanie Baum	Kensey Nash Opts for Mediation in Royalties Dispute With St. Jude Kensey Nash withdraws guidance; shares plummet.
The Motley Fool March 29, 2011 Brian Orelli	Medtronic's Exciting New Toys The device maker received multiple approvals in less than a week.
The Motley Fool July 15, 2011 Arundhati Parmar	St. Jude Medical's Novel Heart Disease Diagnostic Tool Cleared in Europe St. Jude has an inventive new heart disease treatment.
The Motley Fool January 26, 2007	Can St. Jude Make It Better? Fool by Numbers The medical device maker released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool February 22, 2006 Stephen D. Simpson	Medtronic's Minor Miss Sluggish sales in several market categories might spook investors.
The Motley Fool October 20, 2009 Robert Steyer	The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it.
BusinessWeek December 8, 2003 Gene G. Marcial	Medamicus: The Pulse Is Rising Medamicus, a small outfit that supplies medical-device giants, recently purchased Biomec Cardiovascular. Analysts think this makes the stock attractive.
The Motley Fool February 17, 2005 Stephen D. Simpson	Is Medtronic's Heartbeat Slowing? Will gradually decelerating growth lead to a multiple contraction on the medical device maker's stock?
The Motley Fool May 25, 2010 Brian Orelli	Medtronic Gets Tossed Out With the Bathwater A bad day to report good news.
The Motley Fool October 23, 2006 Michael P. Cecil	Are Pacemaker Prices Heading for a Fall? Medicare law changes may drive the amount that hospitals can pay for pacemakers. Will device makers be forced to lower prices? Investors, take note.
The Motley Fool March 16, 2010 Brian Orelli	No Matter What You Call It, It Still Stinks A recall over a paperwork issue? What have you guys been doing? Announcing a recall of your heart defibrillators during a major cardiology meeting probably isn't the best move
The Motley Fool January 25, 2011 Jason Moser	Finding Large Caps for a Winning Portfolio A screen for six large-cap ideas, picking two to add to the watchlist.
The Motley Fool November 9, 2005 Stephen D. Simpson	Greatbatch Keeps Growth Pumping Demand for implantable medical electronics keeps this battery and component maker humming. Investors new to this stock and/or medical technology in general will need to exercise some patience.